Market research
CATB Catabasis Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 110M
- P/E ratio
- Not available
- Analyst target
- 23
- Dividend yield
- 0.0%
- Beta
- 1.66
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US04635X1028
- Market cap
- 110M
- P/E ratio
- Not available
- Analyst target
- 23
- Dividend yield
- 0.0%
- Beta
- 1.66
About
About Catabasis Pharmaceuticals Inc
Catabasis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. The company's lead product candidate is QLS-215, a monoclonal antibody inhibitor of plasma kallikrein that is in preclinical development for the treatment of hereditary angioedema, a rare, debilitating and potentially life-threatening disease. The company was incorporated in 2008 and is based in Boston, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CATB discussion.
5 years, 4 months ago
Catabasis Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 26.3% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Catabasis Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 35.8% to $-9M since the same quarter in the previous year.
Finally, its free cash flow fell by 3.7% to $-8M since the same quarter in the previous year.
Based on the above factors, Catabasis Pharmaceuticals, Inc gets an overall score of 1/5.